Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Hagenbeek · SciRah

Researcher profile · Semantic Scholar

A. Hagenbeek

Share profile

A. Hagenbeek — researcher profile on SciRah

h-index: 58
Works: 299
Citations: 23K

Most-cited papers

Revised response criteria for malignant lymphoma.
B. D. Cheson, B. Pfistner, M. Juweid, R. Gascoyne +16 more
2007Journal of Clinical Oncology4,491 citations Open access
Semantic Scholar
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
G. Salles, J. Seymour, F. Offner, A. López-Guillermo +26 more
2011The Lancet1,044 citations
Semantic Scholar
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
C. Fermé, H. Eghbali, J. Meerwaldt, C. Rieux +31 more
2007New England Journal of Medicine382 citations Open access
Semantic Scholar
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
A. Younes, P. Hilden, B. Coiffier, A. Hagenbeek +46 more
2017Annals of Oncology335 citations Open access
Semantic Scholar
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.
M. V. van Oers, M. Van Glabbeke, L. Giurgea, R. Klasa +7 more
2010Journal of Clinical Oncology321 citations Open access
Semantic Scholar
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
M. Palanca-Wessels, M. Czuczman, G. Salles, S. Assouline +17 more
2015The Lancet Oncology285 citations
Semantic Scholar
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.
A. Hagenbeek, O. Gadeberg, P. Johnson, L. Pedersen +13 more
2008Blood265 citations Open access
Semantic Scholar
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
F. Morschhauser, J. Radford, A. van Hoof, U. Vitolo +16 more
2008Journal of Clinical Oncology263 citations
Semantic Scholar
Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
A. Rosenwald, S. Bens, R. Advani, S. Barrans +32 more
2019Journal of Clinical Oncology226 citations Open access
Semantic Scholar
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
F. Morschhauser, I. Flinn, R. Advani, L. Sehn +19 more
2019The Lancet Haematology221 citations Open access
Semantic Scholar
Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.
G. Salles, D. de Jong, Wan-Ling Xie, A. Rosenwald +17 more
2011Blood214 citations Open access
Semantic Scholar
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
G. V. Van Imhoff, A. McMillan, M. Matasar, J. Radford +14 more
2017Journal of Clinical Oncology206 citations Open access
Semantic Scholar
90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.
F. Morschhauser, J. Radford, A. van Hoof, B. Botto +8 more
2013Journal of Clinical Oncology189 citations
Semantic Scholar
Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols
D. de Jong, Ad Koster, A. Hagenbeek, J. Raemaekers +4 more
2009Haematologica150 citations Open access
Semantic Scholar
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.
M. Czuczman, L. Fayad, V. Delwail, G. Cartron +16 more
2012Blood127 citations Open access
Semantic Scholar
The therapeutic use of rituximab in non-Hodgkin's lymphoma.
R. Marcus, A. Hagenbeek
2007European journal of haematology. Supplementum110 citations
Semantic Scholar
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.
Q. Shi, C. Flowers, W. Hiddemann, R. Marcus +19 more
2017Journal of Clinical Oncology106 citations Open access
Semantic Scholar
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
M. Kersten, J. Driessen, J. Zijlstra, W. Plattel +16 more
2020Haematologica99 citations Open access
Semantic Scholar
Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy
G. Salles, J. Seymour, P. Feugier, F. Offner +25 more
201393 citations
Semantic Scholar
CD20-targeted therapy: the next generation of antibodies.
T. van Meerten, A. Hagenbeek
2010Seminars in hematology (Print)90 citations
Semantic Scholar
Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.
N. Heutte, H. Flechtner, N. Mounier, W. A. Mellink +39 more
2009The Lancet Oncology89 citations
Semantic Scholar
High‐dose Ara‐C and beam with autograft rescue in R‐CHOP responsive mantle cell lymphoma patients
M. B. van T' Veer, D. de Jong, M. Mackenzie, H. Kluin-Nelemans +4 more
2009British Journal of Haematology68 citations Open access
Semantic Scholar
C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia.
D. Wouters, F. Stephan, P. Strengers, M. de Haas +4 more
2013Blood65 citations
Semantic Scholar
B-cell involvement in chronic graft-versus-host disease
R. Kapur, S. Ebeling, A. Hagenbeek
2008Haematologica63 citations Open access
Semantic Scholar
In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection.
Sophia Sobesky, L. Mammadova, M. Cirillo, E. Drees +22 more
2021i Medicina62 citations Open access
Semantic Scholar
The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium
B. Sander, D. de Jong, A. Rosenwald, Wan-Ling Xie +18 more
2014Haematologica60 citations Open access
Semantic Scholar
BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.
M. V. van Oers, Evelyn Tönnissen, M. Van Glabbeke, L. Giurgea +9 more
2010Journal of Clinical Oncology55 citations
Semantic Scholar
Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium
W. Stevens, Matias Mendeville, R. Redd, A. Clear +24 more
2017Haematologica50 citations Open access
Semantic Scholar
Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non- Hodgkin’s Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
M. V. van Oers, M. Van Glabbeke, L. Baila, Livia Giurgia +5 more
200847 citations
Semantic Scholar
CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
T. van Meerten, A. Hagenbeek
2009Netherlands Journal of Medicine46 citations
Semantic Scholar
Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.
L. Goff, K. Summers, S. Iqbal, J. Kuhlmann +7 more
2009Journal of Clinical Oncology43 citations
Semantic Scholar
Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma.
A. Hagenbeek, L. Fayad, V. Delwail, J. Rossi +14 more
200941 citations
Semantic Scholar
Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
F. Morschhauser, I. Flinn, R. Advani, C. Diefenbach +17 more
201438 citations
Semantic Scholar
HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist rituximab-mediated lysis
T. van Meerten, H. Rozemuller, S. Hol, P. Moerer +7 more
2010Haematologica35 citations Open access
Semantic Scholar
Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study
A. Hagenbeek, H. Mooij, J. Zijlstra, P. Lugtenburg +8 more
2018Haematologica34 citations Open access
Semantic Scholar
Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis
H. Struemper, M. Sale, B. Patel, M. Østergaard +5 more
2014Journal of clinical pharmacology30 citations
Semantic Scholar
Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial
A. Delaloye, C. Antonescu, T. Louton, J. Kuhlmann +1 more
2009Journal of Nuclear Medicine24 citations Open access
Semantic Scholar
Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study
A. Hagenbeek, J. Zijlstra, W. Plattel, F. Morschhauser +11 more
2018Blood23 citations Open access
Semantic Scholar
Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).
F. Morschhauser, I. Flinn, R. Advani, L. Sehn +16 more
201423 citations
Semantic Scholar
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)
G. V. Van Imhoff, A. McMillan, M. Matasar, J. Radford +14 more
201423 citations Open access
Semantic Scholar
Novel antibodies against follicular non-Hodgkin's lymphoma.
T. van Meerten, A. Hagenbeek
2011Baillière's Best Practice & Research: Clinical Haematology23 citations
Semantic Scholar
90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients
A. Hagenbeek, J. Radford, A. van Hoof, U. Vitolo +7 more
201023 citations
Semantic Scholar
Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level.
R. Advani, I. Flinn, J. Sharman, C. Diefenbach +16 more
201522 citations
Semantic Scholar
Diversity in antibody-based approaches to non-Hodgkin lymphoma
D. Maloney, F. Morschhauser, Ola Lindén, A. Hagenbeek +1 more
2010Leukemia and Lymphoma15 citations
Semantic Scholar
Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies
A. Kater, S. Tonino, M. Kersten, A. Hagenbeek +6 more
201312 citations
Semantic Scholar
Costs of haematological disease high and rising.
T. Green, D. Bron, C. Chomienne, T. de Wit +8 more
2016The Lancet Haematology10 citations
Semantic Scholar
Optimising the lymphoma response criteria in the era of targeted therapy.
A. Younes, A. Hagenbeek, B. Coiffier
2011The Lancet Oncology10 citations
Semantic Scholar
Quality of Life in hematology: European Hematology Association theme of the year … and years to come
C. Chomienne, M. Guenova, A. Hagenbeek, C. Lacombe +4 more
2013Haematologica9 citations Open access
Semantic Scholar
Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy.
G. Salles, J. Catalano, P. Feugier, F. Offner +24 more
20109 citations
Semantic Scholar
Fair Pricing of Innovative Medicines: An EHA Position Paper
A. Hagenbeek, J. Gribben, U. Jäger, Peter Kapitein +4 more
2020HemaSphere8 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Salles×18
Invite
G. Salles — researcher profile on SciRah
F. Morschhauser×13
Invite
F. Morschhauser — researcher profile on SciRah
H. Tilly×10
Invite
H. Tilly — researcher profile on SciRah
L. Sehn×10
Invite
L. Sehn — researcher profile on SciRah

×8

Invite

M. V. van Oers — researcher profile on SciRah

Invite

J. Radford — researcher profile on SciRah

Invite

M. Kersten — researcher profile on SciRah

Invite

R. Advani — researcher profile on SciRah

Invite

D. de Jong — researcher profile on SciRah

Invite

B. Coiffier — researcher profile on SciRah

Invite

M. Dreyling — researcher profile on SciRah

Invite

P. Brice — researcher profile on SciRah